Personalized Medicine
-
Unlocking the Potential of AI-Driven Biomarkers: A New Era in Personalized Cancer Care
By leveraging AI and machine learning, researchers can analyze complex data sets, identify novel biomarkers, and provide more effective and tailored treatment options for cancer patients.
-
Personalized Medicine Is Revolutionizing the Role of Pharma Companies in the Healthcare Landscape
The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Consumer / Employer, Health Tech
Direct-To-Consumer Startup for Functional Medicine Launches
Malla, a startup that launched Wednesday, is trying to make functional, personalized medicine more accessible. Consumers can purchase a membership, which includes one-on-one video sessions with a practitioner, messaging, personalized care plans and tracking.
-
VC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
Oncology Ventures recently announced investments in three cancer startups — VivorCare, Gabbi and Health Universe. The fund’s founding partner said each company demonstrated an ability to tackle a specific problem within the cancer care space, such as enabling earlier breast cancer diagnoses and providing personalized care plans for cancer survivors.
-
MedCity Influencers, BioPharma
Improving Value-based Care with Optimized Drug Therapy
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
-
2 Changes Siddhartha Mukherjee Is Calling for in Cancer Care
If the medical field wants to make serious progress on the Cancer Moonshot effort, it must expand its definition of personalized medicine and explore fresh approaches to cancer prevention, according to Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and cancer physician at Columbia University Medical Center.
-
BioPharma, Healthcare, Pharma, SYN
Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the fourth CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
-
FDA approves Janssen’s Balversa for urothelial carcinoma – with a personalized medicine approach
The drug was approved along with a companion diagnostic to detect alterations in FGFR2 and FGFR3. The drug is approved for patients with locally advanced or metastatic UC who carry those mutations.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
Centene pledges up to $100M to fund personalized medicine initiative at Washington University
Innovations that emerge from the research will be commercialized through a joint venture between the school and Centene called the ARCH Personalized Medicine Initiative.
-
Do wearables have a role to play in precision medicine?
Biology and artificial intelligence are key aspects of precision medicine, but are wearables part of the equation? Panelists at the Connected Health Conference weighed in.
-
MedCity Influencers, Diagnostics
Consumer interest in genetic testing is exploding. Are providers ready?
A recent study notes that widespread access to personal genetic information – without the knowledge of how to interpret results – can lead to problems ranging from misinterpretation to emotional distress.
-
What all this cancer news means for medicine at large
Precision oncology is the proof of principle. It’s just a matter of time before such personalized tests and treatments become mainstream in other specialties, from rheumatology to endocrinology to psychiatric care.
-
Glooko, Novo Nordisk team on personalized digital diabetes care
The deal gives the Danish pharmaceutical company a consumer-focused technology platform to build on. In return, Glooko gains access to Novo Nordisk’s extensive customer base and deep library of educational content.
-
Medical philanthropy crucial to advance precision medicine
Willing patients who agree to participate in research, and give samples are key to progressing precision medicine and data shows there isn’t any dearth of these medical philanthropists.